Assessment of a drug candidate's effect on ion channels can provide valuable information to estimate the risk or benefit of the candidate for modulating seizure activity.
Charles River’s approach to bioanalysis automation utilizes the Hamilton Microlab STARlet line to provide high throughput, precision and accuracy for large molecule bioanalysis and increase output by up to 600%.
We are happy announce that the 2017 Research Models and Services Catalog has been transitioned to a fully digital platform, supporting our mission to go green.
An in vitro human skin absorption bioequivalence study design by Charles River is the first of its kind to be accepted by the FDA as sufficient to replace clinical testing. This design is now part of our service offerings.
Whole-exome sequencing (WES) results from our syngeneic models are now available globally to help in appropriate model selection.
Regulatory authorities are increasingly focused on this area and have specific guidelines outlining procedures and qualifications that should be performed when evaluating the efficacy of disinfectants in sterile facilities.
Now offering in vitro aerosol product testing using the VITROCELL VC 10® robot.
Our scientists present new and improving techniques for analyzing heavy metals and elements through inductively coupled plasma.
Comprehensive preclinical assessment of stem cell therapies is critical for regulatory approval and to ensure safety in first-in-human clinical trials. Here are some tips to consider for a successful translational cell therapy program.
Agilux’s unique combination of early-stage services, coupled with our existing discovery and safety assessment capabilities, will greatly enhance the speed and efficiency of your lead identification, optimization and candidate selection.